# Tofacitinib Versus Cyclosporine for Steroid Refractory Acute Severe Ulcerative Colitis

> **NCT05112263** · NA · NOT_YET_RECRUITING · sponsor: **Post Graduate Institute of Medical Education and Research, Chandigarh** · enrollment: 96 (estimated)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **DRUG:** Tofacitinib
- **DRUG:** Cyclosporine

## Key facts

- **NCT ID:** NCT05112263
- **Lead sponsor:** Post Graduate Institute of Medical Education and Research, Chandigarh
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-07-01
- **Primary completion:** 2025-12-01
- **Final completion:** 2026-06-01
- **Target enrollment:** 96 (ESTIMATED)
- **Last updated:** 2023-03-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05112263

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05112263, "Tofacitinib Versus Cyclosporine for Steroid Refractory Acute Severe Ulcerative Colitis". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05112263. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*